Ascentage Pharma Group International (NASDAQ:AAPG) Trading Down 6% - Here's What Happened

Key Points

• Ascentage Pharma Group International's stock fell by 6% during mid-day trading, closing at $34.28, significantly lower than its previous close of $36.45.
• The company has a debt-to-equity ratio of 1.31 and significant institutional investments, with several firms acquiring new positions in the second quarter.
• Ascentage Pharma is a clinical-stage biotechnology company focusing on developing therapies for cancers, hepatitis B, and age-related diseases.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - )'s stock price traded down 6% during mid-day trading on Tuesday . The company traded as low as $33.80 and last traded at $34.28. 5,093 shares were traded during trading, a decline of 85% from the average session volume of 34,120 shares. The stock had previously closed at $36.45.

Ascentage Pharma Group International Stock Down 3.4%

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The stock has a 50-day moving average of $40.78 and a 200-day moving average of $33.55.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Tema Etfs LLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth $610,000. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth $391,000. Chevy Chase Trust Holdings LLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth $227,000. Finally, Monashee Investment Management LLC acquired a new position in Ascentage Pharma Group International during the 1st quarter worth $3,511,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.